Regeneron has announced data that could create a niche for its latest cholesterol drug evinacumab in a small group of patients who do not respond to the strongest available medicines.
Bayer’s Xarelto (rivaroxaban) can be funded by the NHS to prevent strokes and heart attacks in high-risk adults with coronary artery disease, NICE has said.
Novartis has announced that its heart failure drug Entresto has failed in a trial that the company hoped would extend its use to a new group of patients with preserved ejection fraction.
A group of scientists from Yale University and the Mayo Clinic are to use an Apple Watch app in a bid to rethink clinical trial design in heart failure.